Although its expression correlates with poor prognosis in colorectal cancer (30) and drug resistance in colon cancer (31), GRM4 agonists can inhibit the proliferation of non-CNS-origin cultured cancer cells, such as bladder cancer cells (32). Here, GRM4 is linked to malignant colon neoplasm.